Point of Care Lipid Test Market - By Product, By Disease Indication, By End Use - Global Forecast, 2025 - 2034

Point of Care Lipid Test Market Size

The global point of care lipid test market size was estimated at USD 694.1 million in 2024. The market is expected to grow from 724.2 million in 2025 to 1.13 billion in 2034, at a CAGR of 5.1% during the forecasted period. The market refers to the business segment that deals with portable diagnostic devices designed to measure blood lipid levels such as cholesterol and triglycerides outside of traditional laboratories. These devices provide quick, on-the-spot results, making them highly valuable in clinical settings, primary care, and home use.
 

The increasing predominance of cardiovascular diseases within the world is driving the development of the point of care lipid testing market. With conditions such as coronary artery disease, stroke, and hypertension are closely linked to abnormal lipid profiles, including high levels of cholesterol and triglycerides, there’s a requirement for testing solutions that are convenient to get to and use. This highlights the importance of providing people with private and convenient ways to monitor their health, without the barriers of traditional visits.
 

For instance, according to World Health Organization (WHO) in 2021, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. The rising predominance of CVDs highlights the requirement for private, trustable testing packs that help people to screen their wellbeing.
 

Healthcare system worldwide is moving from treatment-based models to preventive care, the demand for proactive diagnostic tools such as point-of-care testing market size was over USD 38.5 billion in 2022, lipid tests is on the rise. People are becoming more aware of the importance of early detection and continuous monitoring of chronic conditions, especially those related to heart health, obesity, and diabetes.
 

This awareness is fuelling interest in convenient and rapid testing solutions that help individuals track their health regularly, which is stimulating the requirement for easy-to-use, trustful testing choices that give speedy and correct results. Many continuous innovations are happening in these testing instruments, and they are getting more exact and user-friendly, making them a suitable alternative.
 

Point of Care Lipid Test Market Trends

• Recent developments in the point of care lipid testing technology have improved the accuracy and reliability of these kits. Now a days modern test utilizes various new methods such as advanced digital platform which give precise results. For example, a few at home test kits use a simple fingerstick method and give results in 10-15 minutes, making it more accessible and less invasive for users.
   
• The awareness about preventive CVDs is increasing and so does the demand for testing instruments. For instance, Abbott’s Afinion Lipid Panel, designed for use with the Afinion 2 and AS100 analyzers, allows healthcare providers to perform a full lipid profile test (TC, HDL, LDL, triglycerides) with just one fingerstick blood sample in only 7 minutes. The system is CLIA-waived and supports immediate risk assessment and treatment decisions, making it highly efficient for both primary care settings and remote locations.
   
• Moreover, the global rise in lifestyle-related disorders such as obesity, hypertension, and type 2 diabetes is creating an urgent need for frequent and accessible lipid monitoring. For instance, in 2025 the World Health Organization (WHO) reported that over 390 million children and adolescents aged 5–19 years were overweight in 2022, including 160 million who were living with obesity. The increase in these rates is also stimulating the demand for point of care lipid testing solutions that allow people to monitor their health.
   

Point of Care Lipid Test Market Analysis

Based on the product, the market is segmented into instruments and consumables. The consumables segment held revenue of USD 401 million in 2024, and the segment is poised for significant growth at a CAGR of 5% during the forecast period.  
 

• The growth of this segment is highly accelerated due to the rise in cases of CVDs globally as reported by the WHO, which significantly contribute to the demand for testing solutions. Consumables including test strips, reagent cartridges are essential components of every lipid test. Their single-use nature results in repeat purchases, especially as point-of-care testing becomes more widely integrated into primary care, outpatient clinics, and home-based monitoring, which allows the individuals to test during their own convenience.
   
• The shift toward rapid, user-friendly diagnostic solutions is accelerating demand for disposable consumables, which not only streamline the testing process but also enhance accuracy, hygiene, and convenience. With more healthcare providers and patients opting for immediate lipid profiling at the point of care, recurring use of consumables is stimulating the market.
   
• Therefore, as the demand for more advanced and effective diagnostic tools continues to rise, the consumables segment is anticipated to remain a critical part, contributing to the market growth.

Based on the disease indication, the point of care lipid test market is segmented into lipid and lipoprotein disorder, atherosclerosis, liver and renal diseases, diabetes mellitus, and other disease indication. The lipid and lipoprotein disorder segment dominated the market with a market share of 40.4% in 2024.
 

• This dominance is largely attributed to the growing global incidence of dyslipidemia, including conditions such as hypercholesterolemia, familial lipid abnormalities, and related inherited disorders. These conditions are major contributors to cardiovascular diseases, which continue to be the primary cause of death worldwide.
   
• A 2024 report by the National Institutes of Health (NIH) highlights that lipid imbalances are among the most manageable risk factors linked to heart disease. This has increased the urgency for early and routine lipid screening, encouraging healthcare professionals to shift toward fast, point-of-care diagnostic options. POC lipid testing offers rapid, accurate results at the patient’s location, enabling quicker clinical decisions and improved disease management.
   
• The high clinical relevance and urgency associated with detecting lipid abnormalities support the widespread adoption of these tests. Physicians, especially in cardiology and internal medicine, prioritize lipid testing as part of preventive care.
   

Based on end use, the point of care lipid test market is segmented into hospital, clinics, diagnostic laboratories and other end users. The hospital segment is experiencing the fastest growth in the market with a market share of 38.2% in 2024.
 

• Hospitals have special departments that usually bring together teams of highly trained specialists and skilled nursing staff who are experienced in handling the patients. Their deep clinical knowledge helps in making more accurate diagnosis and better care for patients.
   
• These institutions are increasingly adopting advanced digital infrastructure, such as cloud-integrated platforms and AI-powered data management tools, which enable real-time access and analysis of critical patient information. This supports faster and more informed clinical decisions.
   
• Many hospitals are also pioneering the use of advanced diagnostic tools, such as the Abbott Afinion System, which offers complete lipid panel results in just minutes. This rapid testing capability is essential for streamlining clinical workflows across emergency settings, routine examinations, and the ongoing management of chronic conditions.
   
• Driven by the rising focus on early diagnosis and value-based care, hospitals are expected to continue leading in the adoption of point-of-care lipid testing. This strengthens their role in improving diagnostic efficiency and reinforces their position as central players in delivering timely, outcome-oriented healthcare.

The U.S. point of care lipid test market is forecasted to reach USD 440.4 million by 2034.
 

• In the U.S., the prevalence of lipid disorders is steadily increasing. According to CDC data from 2024, approximately 86 million adults aged 20 and older have total cholesterol levels above 200 mg/dL, and nearly 25 million have levels exceeding 240 mg/Dl placing them at significantly higher risk for cardiovascular diseases.
   
• This alarming trend has heightened public awareness about the importance of routine lipid screening and early risk identification, thereby boosting demand for point-of-care (POC) lipid testing solutions. With more people recognizing the need for regular testing and early detection, the demand for point of care lipid testing kits is on the rise.
   
• This growing awareness among the population is driving the market toward more convenient and accessible healthcare solutions. With the rising prevalence of lipid disorders, the need for timely and easy-to-use diagnostic tools has become more critical than ever. This trend is expected to continue contributing to the growth of market in the U.S.
   

Europe:

The point of care lipid test market in the UK is projected to grow significantly from 2025 to 2034.
 

• The countries well established healthcare system and the rising demand for advanced diagnostic tools are the key factors propelling the growth of the market in the country.
   
• A recent survey in February 2024 revealed that 86% of UK’s population believe faster testing and diagnosis could help reduce the NHS backlog, highlighting a strong public interest in accessible diagnostic options.
   
• This also indicates a growing demand for convenient testing solutions that allow patients to receive quicker results.
   

Asia Pacific:

The point of care lipid test market in the Japan is projected to grow significantly from 2025 to 2034.
 

• Japan’s rapidly aging population is significantly influencing the demand for age-related diagnostic interventions, particularly in cardiovascular care, thereby boosting the adoption of point-of-care lipid testing.
   
• For example, in 2023 projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above which was about one-third of the population.
   
• The aging population is contributing to a higher incidence of lipid disorders and associated chronic illnesses, thereby increasing the demand for quicker and more accessible diagnostic options such as point-of-care (POC) lipid testing.
   
• Furthermore, as healthcare infrastructure continues to advance and greater emphasis is placed on preventive health strategies, the integration and uptake of innovative lipid testing technologies are projected to grow significantly.
   

Middle East and Africa:

The point of care lipid test market in the Saudi Arabia is projected to grow significantly from 2025 to 2034.
 

• The growth of the market is highly influenced by the increasing investment in healthcare infrastructure, including advanced medical devices, diagnostic tools such point of care lipid testing instruments is propelling the growth of the market in the country.
   
• Under Saudi Arabia’s Vision 2030, the government plans to invest over USD 65 billion to enhance healthcare infrastructure, which includes the development of health clusters and the expansion of health services.
   
• Therefore, these efforts are expected to transform the healthcare landscape in Saudi Arabia, making testing options more accessible and widely adopted by consumers for managing their health.
   

Point of Care Lipid Test Market Share

The market for point-of-care (POC) lipid test is highly competitive, with both global leaders and emerging players continuously innovating to develop faster, more accurate, and user-friendly diagnostic solutions. In terms of revenue, the market is primarily dominated by top companies such as Abbott Laboratories, F. Hoffmann-La Roche, Nova Biomedical, SD Biosensor, and Menarini Group, which collectively account for 40% of the global market share.
 

These companies are focused on advancing lipid testing technologies through integration with digital health platforms, improved portability, and rapid turnaround times. By prioritizing precision, reliability, and patient convenience, these key players are reinforcing their leadership positions and shaping the future growth of the POC lipid test market.
 

Point of Care Lipid Test Market Companies

Some of the eminent market participants operating in the point-of-care (POC) lipid test industry include:

• Abbott Laboratories
• Callegari
• F. Hoffmann-La Roche
• Kanlife
• Menarini Group
• MiCoBio
• Nova Biomedical
• SD Biosensor
• Sinocare
• VivaChek Biotech

• Abbott Laboratories deals in diagnostics, medical devices, nutrition and branded generic pharmaceuticals. The company has established a global presence in more than 160 countries.
   
• F. Hoffmann-La Roche Ltd is one of the global leaders in pharmaceuticals and diagnostics, headquartered in Basel, Switzerland. The company specializes in innovative medicines and diagnostic tests, particularly in oncology, immunology, infectious diseases, and neuroscience.
   

Point of Care Lipid Test Industry News:

• In July 2024, Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology, bolstering its diagnostics portfolio. This integration introduces a versatile platform capable of conducting multiple immunoassay and clinical chemistry tests on a single device, with potential for future molecular testing. The innovative solution will allow Roche to further expand its offering in decentralised patient care and drive global access to timely and actionable diagnostic results.
   
• In January 2023, Cipla announced the launch of Cippoint, a point- of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. With this launch Cipla has expanded its product offerings for diagnostics laboratories. 
   

The point of care lipid test market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables

Market, By Disease Indication

• Lipid and lipoprotein disorder
  • Endogenous hyperlipemia
  • Tangier disease
  • Hyperlipoproteinemia
  • Familial hypercholesterolemia
  • Other lipid and lipoprotein disorders 
• Atherosclerosis
• Liver and renal diseases
• Diabetes mellitus
• Other disease indication

Market, By End Use

• Hospitals
• Clinics
• Diagnostic laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE